期刊文献+

冷冻消融联合GM-CSF治疗对肾癌小鼠血管生成及细胞增殖的影响 被引量:3

Effects of cryoablation combined with GM-CSF on angiogenesis and cell proliferation in mice with renal carcinoma
下载PDF
导出
摘要 目的探讨冷冻消融联合粒细胞-巨噬细胞集落刺激因子(GM-CSF)治疗对肾癌小鼠血管生成及细胞增殖的影响。方法取40只健康级别为SPF级的BALB小鼠,肾癌细胞株786-0建立荷肾癌小鼠模型,将模型建立成功的荷肾癌小鼠按随机数字表法分A、B、C、D四组,每组10只,A组不做任何处理,B组给予GM-CSF,C组给予冷冻消融处理,D组给予冷冻消融联合GM-CSF治疗,记录小鼠基本生存状态,观察小鼠肿瘤变化情况,绘制瘤体大小折线图,并分别应用HUVEC小管形成实验、MTT法检测各组小鼠血管生成及细胞增殖情况。结果小鼠接种肾癌细胞株786-0后未见明显进食异常现象,有轻度精神萎靡、纳差,接种部位随时间延长而逐渐膨隆,但接种部位表皮未见破溃、出血现象,接种2周时无死亡小鼠,HE染色证实荷肾癌小鼠模型成功建立;A组治疗后1、2、3周时瘤体逐渐增大,B组亦持续增大,但增大幅度较A组小,C组、D组在治疗2周后便可见瘤体缩小,4组小鼠不同时间点的瘤体大小差异有统计学意义(P<0.05);且治疗2周、4周时C、D组小鼠瘤体显著小于A、B组(P<0.05);B、C、D组管腔形成长度、个数均显著低于A组(P<0.05),而D组管腔形成长度、个数显著低于B、C组(P<0.05);B、C、D 3组小鼠细胞治疗24、48、72、96、128h时的细胞增殖抑制率比较差异均有统计学意义(P<0.05),且治疗后72h细胞增殖抑制率最高,至96、128h均有下降,但D组任意时间段的细胞增殖抑制率均显著高于B、C组(P<0.05)。结论冷冻消融联合GM-CSF治疗可显著抑制肾癌小鼠血管生成及细胞增殖,缩小瘤体体积,且安全性良好。 Objective To analyze the effects of cryoablation combined with granulocyte-macrophage colony-stimulating factor(GM-CSF)on angiogenesis and cell proliferation in renal carcinoma mice.Methods 40 BALB mice with the health level at SPF were taken.The renal carcinoma mouse model was established with renal carcinoma cell line 786-0.The mice with renal carcinoma successful establishing the model were randomly divided into A,B,C,and D group.Group A did not execute any treatment,group B was given GM-CSF,group C was given cryoablation treatment and group D was given cryoablation combined with GM-CSF.The basic survival status of the mice was recorded.The tumor changes of the mice were observed.The line chart of tumor size was drawn.The HUVEC tubule formation experiment and MTT were respectively used to detect angiogenesis and cell proliferation in each group.Results After the mice were inoculated with renal carcinoma cell line 786-0,there was no obvious abnormal eating phenomenon with mild energielos,poor appetite.The inoculation site gradually expanded with time.The epidermis of the inoculation site showed no ulceration and bleeding.At 2 weeks after inoculation,there was no death mouse.HE staining confirmed that the mouse model with renal carcinoma was successfully established.In the group A,the tumor gradually increased at 1,2,and 3 weeks after treatment.The tumor in the group A also continued to increase.The increase degree of group A was larger than that of group B.The tumor became small in group C and group D at 2 weeks after treatment.There was statistical significance in the difference of tumor size in the 4 groups at different time points,the tumor size in groups C and D at 2 and 4 weeks after treatment was significantly smaller than that in group A and B(P<0.05).The length and number of lumen formation in group B,C and D were significantly lower than those in group A(P<0.05),while the length and number of lumen formation in group D were significantly lower than those in group B and C(P<0.05).The difference in cell proliferation inhibition rates of the mice in group B,C and D at 24 h,48 h,72 h,96 hand 128 hwas statistically significant the(P<0.05).The inhibition rate of cell proliferation was the highest at 72 hafter treatment,it decreased at 96 hand128 h,the inhibition rate of cell proliferation in group D was significantly higher than that in group B and C at any time(P<0.05).Conclusion Cryoablation combined with GM-CSF therapy can significantly inhibit angiogenesis and cell proliferation in renal carcinoma mice and reduce tumor volume.The safety is good.
作者 沈滔 杜闯 孙勃 SHEN Tao;DU Chuang;SUN Bo(Department of Urology,242 hospital of Shenyang,The Third Affiliated Hospital of Shenyang Medical College,Shertyang 110034,China)
出处 《西部医学》 2019年第2期185-189,共5页 Medical Journal of West China
基金 辽宁省自然科学基金(201602442)
关键词 冷冻消融 GM-CSF 肾癌小鼠 血管生成 细胞增殖 Cryoablation GM-CSF Mice with renal carcinoma Angiogenesis Cell proliferation
  • 相关文献

参考文献11

二级参考文献108

  • 1王琪(综述),林苹(审校).肿瘤浸润性树突状细胞的研究进展[J].中国癌症杂志,2005,15(2):185-188. 被引量:8
  • 2赵文华.恶性肿瘤流行趋势分析及预防的研究[J].天津科技,2006,33(3):38-39. 被引量:37
  • 3马建辉,何志嵩.肾细胞癌诊断治疗指南[M] //那彦群,孙光.中国泌尿外科疾病诊断治疗指南.2009版.北京:人民卫生出版社,2009:4-15.
  • 4顾方六,肾肿瘤[M]//吴阶平.泌尿外科学.上卷.济南:山东科学技术出版社,2004:895-896.
  • 5Radford KJ,Caminschi I. New generation of dendritic cell vac-cines [J] . Hum Vaccin Immunother, 2013 , 9(2) [ Epub aheadof print].
  • 6Cintolo JA,Datta J,Mathew SJ,et al. Dendritic cell-based vac-cines :Barriers and opportunities [ J]. Future Oncol,2012,8(10) ; 1273-1299.
  • 7Mantia-Smaldone GM, Chu CS. A review of dendritic cell therapyfor cancer: Progress and challenges [J]. BioDrugs, 2013 [Epubahead of print].
  • 8Kalinski P, Muthuswamy R, Urban J. Dendritic cells in cancerimmunotherapy: Vaccines and combination immunotherapies [J].Expert Rev Vaccines, 2013,12(3) : 285-295.
  • 9Gattinoni L, Powell DJ, Rosenberg SA, et al. Adoptive immuno-therapy for cancer: Building on success [ J]. Nat Rev Immunol,2006,6(5):383-393.
  • 10Koido S, Homma S, Okamoto M, et al. Combined TLR2/4-acti-vated dendritic/ tumor cell fusions induce augmented cytotoxic Tlymphocytes [ J]. PLoS One, 2013 , 8(3) : e59280.

共引文献76

同被引文献24

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部